This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ullrich, E. Articles by Zitvogel, L. Search for Related Content PubMed PubMed Citation Articles by Ullrich, E. Articles by Zitvogel, L. Related Collections Therapeutics and Targets Therapeutics and Targets: Drug Mechanisms and Resistance Cancer Immunology: Adaptive Immunity

Therapy-Induced Tumor Immunosurveillance Involves IFN-Producing Killer Dendritic Cells

¹ Institut National de la Santé et de la Recherche Médicale, U805, Faculté de Médecine Kremlin Bicêtre, and ² Institut National de la Santé et de la Recherche Médicale, Unit "Apoptosis, Cancer and Immunity," Institut Gustave Roussy, Villejuif, France; and ³ Department of Gastroenterology, Hôpital Pitié Salpétrière, AP-HP, Paris, France

Requests for reprints: Laurence Zitvogel, U805 Institut National de la Sante et de la Recherche Medicale, and CBT507 Center of Clinical Investigations, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France. Phone: 33-1-42-11-50-41; Fax: 33-1-42-11-60-94; E-mail: zitvogel{at}igr.fr.

A unique class of IFN-producing killer dendritic cells (IKDC) resembling natural killer cells has been defined that can recognize and lyse tumor cells through a tumor necrosis factor–related apoptosis-inducing ligand–dependent mechanism. IKDC may mediate the host-dependent antitumor activity of Gleevec/STI571 and other therapeutics that can inhibit the c-kit tyrosine kinase. IKDC represent an important new component of the innate immune system responding to cancer. [Cancer Res 2007;67(3):851–3]

This article has been cited by other articles:

				K. A. Sauer, J. H. Maxeiner, R. Karwot, P. Scholtes, H. A. Lehr, M. Birkenbach, R. S. Blumberg, and S. Finotto Immunosurveillance of Lung Melanoma Metastasis in EBI-3-Deficient Mice Mediated by CD8+ T Cells J. Immunol., November 1, 2008; 181(9): 6148 - 6157. [Abstract] [Full Text] [PDF]

				N. Himoudi, S. Nabarro, J. Buddle, A. Eddaoudi, A. J. Thrasher, and J. Anderson Bone Marrow-Derived IFN-Producing Killer Dendritic Cells Account for the Tumoricidal Activity of Unpulsed Dendritic Cells J. Immunol., November 1, 2008; 181(9): 6654 - 6663. [Abstract] [Full Text] [PDF]

				K. S. Hill, F. Errington, L. P. Steele, A. Merrick, R. Morgan, P. J. Selby, N. T. Georgopoulos, D. M. O'Donnell, and A. A. Melcher OK432-Activated Human Dendritic Cells Kill Tumor Cells via CD40/CD40 Ligand Interactions J. Immunol., September 1, 2008; 181(5): 3108 - 3115. [Abstract] [Full Text] [PDF]

				S. Mariotti, V. Sargentini, C. Marcantonio, E. Todero, R. Teloni, M. C. Gagliardi, A. R. Ciccaglione, and R. Nisini T-cell-mediated and antigen-dependent differentiation of human monocyte into different dendritic cell subsets: a feedback control of Th1/Th2 responses FASEB J, September 1, 2008; 22(9): 3370 - 3379. [Abstract] [Full Text] [PDF]

				E. Ullrich, M. Bonmort, G. Mignot, B. Jacobs, D. Bosisio, S. Sozzani, A. Jalil, F. Louache, E. Bulanova, F. Geissman, et al. Trans-Presentation of IL-15 Dictates IFN-Producing Killer Dendritic Cells Effector Functions J. Immunol., June 15, 2008; 180(12): 7887 - 7897. [Abstract] [Full Text] [PDF]

				G. Mignot, E. Ullrich, M. Bonmort, C. Menard, L. Apetoh, J. Taieb, D. Bosisio, S. Sozzani, M. Ferrantini, J. Schmitz, et al. The Critical Role of IL-15 in the Antitumor Effects Mediated by the Combination Therapy Imatinib and IL-2 J. Immunol., May 15, 2008; 180(10): 6477 - 6483. [Abstract] [Full Text] [PDF]

				C. A.J. Vosshenrich, S. Lesjean-Pottier, M. Hasan, O. Richard-Le Goff, E. Corcuff, O. Mandelboim, and J. P. Di Santo CD11cloB220+ interferon-producing killer dendritic cells are activated natural killer cells J. Exp. Med., October 29, 2007; 204(11): 2569 - 2578. [Abstract] [Full Text] [PDF]